A novel cancer vaccine shows great promise as it heads to human trials
Researchers concluded that the peptide called PD1-Vaxx triggered a broader polyclonal antibody response
Faisal Khan
Faisal Khan
4 days ago·4 min read

Once the mega-storm of COVID-19 subsides, researchers and scientists can perhaps get back to addressing some of the other diseases that are plaguing humanity — one of which is Cancer. It is still by far the biggest killer for the global population and despite the best efforts, an effective treatment or virus still eludes us. You might hear about a lot of alternative therapies and treatments, but none make it to mainstream medicine.

I have written about numerous cancer treatments previously — from a breakthrough in Cancer Immunotherapy to various nanoparticles to something as simple as discovering cancer-killing ‘miyabeacin’ in the Willow tree. We keep hearing of a growing number of promising cancer treatments being tested, but none so far has reached the stage where one of them can be used in the real world. Maybe the one we are going to discuss today would be the one.

Researchers from the Ohio State University Comprehensive Cancer Center, University of California, Los Angeles, and Tanios Bekaii-Saab, Mayo Clinic (Phoenix, AZ) have now developed a therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells — thus enabling them to attack and destroy a tumor. Animal trials conducted showed 90% effectiveness, when combined with a second immunotherapy drug.
Image for post
Image for post

“First, PD1-Vaxx activates both B- and T-cell functions to promote tumor clearance. Second, the treatment is targeted to block signaling pathways that are crucial for tumor growth and maintenance. By giving this vaccine in combination with an immunotherapy drug, we are essentially super-charging and specifically directing the immune system to target and kill cancer cells.”

~ Pravin Kaumaya, First Author of the Study Medium.***